HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION POWDER FOR SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

HYDROCORTISONE (HYDROCORTISONE SODIUM SUCCINATE)

Beschikbaar vanaf:

TEVA CANADA LIMITED

ATC-code:

H02AB09

INN (Algemene Internationale Benaming):

HYDROCORTISONE

Dosering:

250MG

farmaceutische vorm:

POWDER FOR SOLUTION

Samenstelling:

HYDROCORTISONE (HYDROCORTISONE SODIUM SUCCINATE) 250MG

Toedieningsweg:

INTRAMUSCULAR

Eenheden in pakket:

10

Prescription-type:

Prescription

Therapeutisch gebied:

ADRENALS

Product samenvatting:

Active ingredient group (AIG) number: 0106344004; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2018-04-30

Productkenmerken

page 1 of 7
PACKAGE INSERT
Sterile Powder
PR
HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION
BP
_ _
Glucocorticoid
_ _
ACTION AND CLINICAL PHARMACOLOGY
Hydrocortisone sodium succinate is a corticosteroid, and a highly
water soluble ester derivative of
hydrocortisone. It has the same metabolic and anti inflammatory
actions as hydrocortisone. High blood
levels of hydrocortisone are attained following intravenous injection.
Pharmacological effects have been noted within minutes and persist for
variable periods of time.
Excretion occurs primarily within 12 hours so that if high blood
levels need to be maintained
hydrocortisone injections are to be repeated every 4 to 6 hours. The
intravenous route is preferred for
initial emergency treatment.
INDICATIONS AND CLINICAL USE
Corticosteroid therapy is an adjunct to, and not a replacement for,
conventional therapy.
1. ENDOCRINE DISORDERS
Congenital adrenal hyperplasia; Hypercalcemia associated with cancer;
Primary or secondary
adrenocortical insufficiency or acute adrenocortical insufficiency
(hydrocortisone is the drug of
choice - it may also be used to supplement synthetic analogs);
Patients with known adrenal
insufficiency or when adrenocortical reserve is doubtful;
Preoperatively; Serious trauma or illness;
Shock unresponsive to conventional therapy if adrenocortical
insufficiency exists or is suspected;
Nonsuppurative thyroiditis.
2. ALLERGIC STATES
Acute non infectious laryngeal oedema (though epinephrine is the drug
of first choice);
Control of severe or incapacitating allergic reactions:
Drug hypersensitivity reactions; Serum sickness; Seasonal or
perennial allergic rhinitis;
Urticarial transfusion reactions.
3. RESPIRATORY DISEASES
Aspiration
pneumonitis;
Berylliosis;
Bronchial
asthma;
Concurrently
with
appropriate
antituberculous chemotherapy in fulminating or disseminated pulmonary
tuberculosis; Loeffler's
syndrome not manageable by other means; Symptomatic sarcoidosis.
4. DERMATOLOGIC DISEASES
Atopic dermatitis; Bullous dermatitis herpetiformis; Contact
dermatiti